Paper41599403
Triazole and Pyrazole Hybrids of Electrophilic Natural Products as Promising Anticancer Agents.
Fermo AD and 4 others. Molecules, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Triazole and Pyrazole Hybrids of Electrophilic Natural Products as Promising Anticancer Agents. Papers, record 41599403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41599403
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Triazole and Pyrazole Hybrids of Electrophilic Natural Products as Promising Anticancer Agents.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pyrazoles | Major topic |
| Antineoplastic Agents | Major topic |
| Biological Products | Major topic |
| Triazoles | Major topic |
| Humans | |
| Molecular Structure | |
| Animals |
Source PubMed
References80
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39193301 | Design, synthesis and potent anti-pancreatic cancer activity of new pyrazole derivatives bearing chalcone, thiazole and thiadiazole moieties: gene expression, DNA fragmentation, cell cycle arrest and SAR. | RSC Adv | 2024 | https://conductscience.org/library/papers/39193301 | PubMed |
| 2 | 25339989 | Activity artifacts in drug discovery and different facets of compound promiscuity. | F1000Res | 2014 | https://conductscience.org/library/papers/25339989 | PubMed |
| 3 | 12556221 | Indisulam: an anticancer sulfonamide in clinical development. | Expert Opin Investig Drugs | 2003 | https://conductscience.org/library/papers/12556221 | PubMed |
| 4 | 38117940 | Identification of novel sulfathiazole-triazolo-chalcone hybrids as VEGFR-2/EGFR dual inhibitors with antiangiogenic activity and apoptotic induction. | Arch Pharm (Weinheim) | 2024 | https://conductscience.org/library/papers/38117940 | PubMed |
| 5 | 34939695 | Anticancer activity of novel 3-(furan-2-yl)pyrazolyl and 3-(thiophen-2-yl)pyrazolyl hybrid chalcones: Synthesis and in vitro studies. | Arch Pharm (Weinheim) | 2022 | https://conductscience.org/library/papers/34939695 | PubMed |
| 6 | 28488435 | Chalcone: A Privileged Structure in Medicinal Chemistry. | Chem Rev | 2017 | https://conductscience.org/library/papers/28488435 | PubMed |
| 7 | 31986406 | 1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226. | Eur J Med Chem | 2020 | https://conductscience.org/library/papers/31986406 | PubMed |
| 8 | 37331408 | Design, synthesis, in vitro and in silico evaluation of anti-colorectal cancer activity of curcumin analogues containing 1,3-diphenyl-1H-pyrazole targeting EGFR tyrosine kinase. | Biochim Biophys Acta Gen Subj | 2023 | https://conductscience.org/library/papers/37331408 | PubMed |
| 9 | 36651540 | Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents via inhibition of PI3K/Akt/mTOR signalling pathway. | Acta Pharm | 2022 | https://conductscience.org/library/papers/36651540 | PubMed |
| 10 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 11 | 35964843 | Synthesis and biological testing of 3,5-bis(arylidene)-4-piperidone conjugates with 2,5-dihydro-5H-1,2-oxaphospholenes. | Bioorg Med Chem Lett | 2022 | https://conductscience.org/library/papers/35964843 | PubMed |
| 12 | 11433435 | Click Chemistry: Diverse Chemical Function from a Few Good Reactions. | Angew Chem Int Ed Engl | 2001 | https://conductscience.org/library/papers/11433435 | PubMed |
| 13 | 39496648 | Design, in silico studies and biological evaluation of novel chalcones tethered triazolo[3,4-a]isoquinoline as EGFR inhibitors targeting resistance in non-small cell lung cancer. | Sci Rep | 2024 | https://conductscience.org/library/papers/39496648 | PubMed |
| 14 | 27697050 | Hybrid Compounds as Multitarget Directed Anticancer Agents. | Curr Top Med Chem | 2017 | https://conductscience.org/library/papers/27697050 | PubMed |
| 15 | 28685693 | Multi-Targeted Anticancer Agents. | Curr Top Med Chem | 2017 | https://conductscience.org/library/papers/28685693 | PubMed |
| 16 | 38998962 | Synthesis, Anticancer Activity, and Molecular Docking of New 1,2,3-Triazole Linked Tetrahydrocurcumin Derivatives. | Molecules | 2024 | https://conductscience.org/library/papers/38998962 | PubMed |
| 17 | 34572538 | Tailored Functionalization of Natural Phenols to Improve Biological Activity. | Biomolecules | 2021 | https://conductscience.org/library/papers/34572538 | PubMed |
| 18 | 35358822 | Apoptosis induction, PARP-1 inhibition, and cell cycle analysis of leukemia cancer cells treated with novel synthetic 1,2,3-triazole-chalcone conjugates. | Bioorg Chem | 2022 | https://conductscience.org/library/papers/35358822 | PubMed |
| 19 | 16220969 | Designed multiple ligands. An emerging drug discovery paradigm. | J Med Chem | 2005 | https://conductscience.org/library/papers/16220969 | PubMed |
| 20 | 30343043 | Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study. | Pharmacol Rep | 2019 | https://conductscience.org/library/papers/30343043 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41599403
GET https://conductscience.org/api/papers/v1/41599403/references?page=2